IO Biotech, Inc.
DelistedCIK 1865494fmd_1J3K8DH6WHNBVP6B97APHT3RRXManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2020 to Sep 30, 2025, 21 periods
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|
| Research and development | 8 | 30 | 47 | 68 | 71 |
| Total operating expenses | 10 | 41 | 71 | 91 | 95 |
| Operating income | (10) | (41) | (71) | (91) | (95) |
| Interest expense | 0 | 0 | 0 | – | – |
| Other non-operating income (expense) | (2) | (27) | 1 | 6 | 1 |
| Income before taxes | (12) | (68) | (70) | (85) | (94) |
| Income tax expense | – | 0 | 1 | 1 | 1 |
| Net income from continuing operations | – | (68) | (71) | (86) | (95) |
| Net income | (12) | (68) | (71) | (86) | (96) |
| Net income to common shareholders | (15) | (75) | (71) | (86) | (95) |